
The CFTR (cystic fibrosis transmembrane conductance regulator) modulator combination elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was shown to improve clinical outcomes and sweat chloride concentration in patients with cystic fibrosis (CF) and one or two F508del alleles. However, the effect of ELX/TEZ/IVA on CFTR function in the airways and intestines has not been studied. So the study aimed to assess the impact of ELX/TEZ/IVA on CFTR function in the airway and intestinal epithelia in patients with CF and one or two F508del alleles aged 12 years and older. Treatment with ELX/TEZ/IVA effectively improves CFTR function in the airway and intestinal epithelia in patients with CF and one or two F508del alleles.
Like
Save
Share